Sumitomo Mitsui DS Asset Management Company Ltd Sells 26,032 Shares of Moderna, Inc. $MRNA

Sumitomo Mitsui DS Asset Management Company Ltd cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 74.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,931 shares of the company’s stock after selling 26,032 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Moderna were worth $246,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MRNA. Czech National Bank grew its stake in Moderna by 7.0% in the second quarter. Czech National Bank now owns 83,189 shares of the company’s stock valued at $2,295,000 after acquiring an additional 5,409 shares during the period. Douglas Lane & Associates LLC increased its position in shares of Moderna by 6.5% during the 2nd quarter. Douglas Lane & Associates LLC now owns 930,165 shares of the company’s stock valued at $25,663,000 after purchasing an additional 56,648 shares during the last quarter. Strs Ohio purchased a new stake in shares of Moderna during the 1st quarter valued at $2,049,000. Acadian Asset Management LLC increased its position in shares of Moderna by 313.2% during the 1st quarter. Acadian Asset Management LLC now owns 167,499 shares of the company’s stock valued at $4,745,000 after purchasing an additional 126,961 shares during the last quarter. Finally, Belpointe Asset Management LLC purchased a new stake in shares of Moderna during the 1st quarter valued at $232,000. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Bank of America reduced their target price on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research note on Tuesday, July 22nd. Cowen started coverage on shares of Moderna in a research report on Sunday, July 13th. They set a “hold” rating for the company. Wells Fargo & Company reiterated an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Finally, Evercore ISI set a $32.00 price objective on Moderna in a research report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $41.81.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $26.56 on Tuesday. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $67.96. The business has a 50-day simple moving average of $27.44 and a two-hundred day simple moving average of $27.83. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of -3.53 and a beta of 1.93.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business’s quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.